These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37331161)

  • 61. Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
    Tanaka H; Mukai J; Kushibiki K; Mizushima S; Maeda K; Fujimoto Y; Sawada R; Oda M; Okuda H; Yamaki M; Hashiguchi S; Kawai I; Kawaguchi I; Masuda N; Matsushita H
    Vaccine; 2023 Jan; 41(2):365-371. PubMed ID: 36460533
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
    Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
    Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Robust antibody response after a third BNT162b2 vaccine compared to the second among immunocompromised and healthy individuals, a prospective longitudinal cohort study.
    Shapiro Ben David S; Mizrahi B; Rahamim-Cohen D; Supino-Rosin L; Shahar A; Hermoni-Alon S; Fremder Sacerdote A; Irony A; Lazar R; Kalkstein N; Lustig Y; Indenbaum V; Landsberger D; Mizrahi-Reuveni M; Shapira S
    Vaccine; 2022 Jun; 40(30):4038-4045. PubMed ID: 35641358
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.
    Obeid M; Suffiotti M; Pellaton C; Bouchaab H; Cairoli A; Salvadé V; Stevenel C; Hottinger R; Pythoud C; Coutechier L; Molinari L; Trono D; Ribi C; Gottardo R; Fenwick C; Pascual M; Duchosal MA; Peters S; Pantaleo G
    JAMA Oncol; 2022 May; 8(5):e220446. PubMed ID: 35271706
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients.
    Davidov Y; Indenbaum V; Tsaraf K; Cohen-Ezra O; Likhter M; Ben Yakov G; Halperin R; Levy I; Mor O; Agmon-Levin N; Afek A; Rahav G; Lustig Y; Ben Ari Z
    J Hepatol; 2022 Sep; 77(3):702-709. PubMed ID: 35452692
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV.
    Vanetti C; Milazzo L; Ardizzone F; Oreni L; Cappelletti G; Trabattoni D; Biasin M
    AIDS Res Hum Retroviruses; 2023 Sep; 39(9):495-499. PubMed ID: 37031355
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
    Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab.
    Achiron A; Mandel M; Dreyer-Alster S; Magalashvili D; Menascu S; Warszawer Y; Dolev M; Didikin M; Harari G; Sonis P; Falb R; Gurevich M
    Mult Scler Relat Disord; 2023 Apr; 72():104616. PubMed ID: 36933299
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.
    Leung NHL; Cheng SMS; Cohen CA; Martín-Sánchez M; Au NYM; Luk LLH; Tsang LCH; Kwan KKH; Chaothai S; Fung LWC; Cheung AWL; Chan KCK; Li JKC; Ng YY; Kaewpreedee P; Jia JZ; Ip DKM; Poon LLM; Leung GM; Peiris JSM; Valkenburg SA; Cowling BJ
    Lancet Microbe; 2023 Sep; 4(9):e670-e682. PubMed ID: 37549680
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of the Durability of the Immune Humoral Response to COVID-19 Vaccines in Patients With Cancer Undergoing Treatment or Who Received a Stem Cell Transplant.
    Khan QJ; Bivona CR; Martin GA; Zhang J; Liu B; He J; Li KH; Nelson M; Williamson S; Doolittle GC; Sun W; Mudaranthakam DP; Streeter NR; McGuirk JP; Al-Rajabi R; Hoffmann M; Kasi A; Parikh RA; Zhong C; Mitchell L; Pessetto ZY; Pathak H; Ghosh A; LaFaver S; Sharma P; Godwin AK
    JAMA Oncol; 2022 Jul; 8(7):1053-1058. PubMed ID: 35446353
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients.
    Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
    Ups J Med Sci; 2022; 127():. PubMed ID: 36337280
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod.
    Achiron A; Mandel M; Gurevich M; Dreyer-Alster S; Magalashvili D; Sonis P; Dolev M; Menascu S; Harari G; Flechter S; Falb R
    J Neurol; 2022 May; 269(5):2286-2292. PubMed ID: 35235002
    [TBL] [Abstract][Full Text] [Related]  

  • 74. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Demographic and Clinical Factors Associated With Anti-SARS-CoV-2 Antibody Levels After 2 BNT162b2 mRNA Vaccine Doses.
    Nam SY; Jeon SW; Lee HS; Lim HJ; Lee DW; Yoo SS
    JAMA Netw Open; 2022 May; 5(5):e2212996. PubMed ID: 35587345
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study.
    Van Praet J; Reynders M; De Bacquer D; Viaene L; Schoutteten MK; Caluwé R; Doubel P; Heylen L; De Bel AV; Van Vlem B; Steensels D; De Vriese AS
    J Am Soc Nephrol; 2021 Dec; 32(12):3208-3220. PubMed ID: 34588184
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dyslipidemia and SARS-CoV-2 spike antibody titres after the second and third doses of the BNT162b2 vaccine among healthcare workers in Japan.
    Islam Z; Yamamoto S; Mizoue T; Oshiro Y; Inamura N; Konishi M; Ozeki M; Sugiura W; Ohmagari N
    Diabetes Metab Res Rev; 2023 Mar; 39(3):e3606. PubMed ID: 36562447
    [TBL] [Abstract][Full Text] [Related]  

  • 78. SARS-CoV-2 antibody responses before and after a third dose of the BNT162b2 vaccine in Italian healthcare workers aged ≤60 years: One year of surveillance.
    Franzese M; Coppola L; Silva R; Santini SA; Cinquanta L; Ottomano C; Salvatore M; Incoronato M
    Front Immunol; 2022; 13():947187. PubMed ID: 36248864
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cellular and humoral immune responses after a third dose of SARS-CoV-2 mRNA vaccine in lung transplant recipients in Japan.
    Ui M; Hirama T; Akiba M; Honda M; Kikuchi T; Okada Y
    Vaccine; 2023 Jul; 41(31):4534-4540. PubMed ID: 37328349
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
    Tan NH; Geers D; Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Bogers S; van Dijk LLA; Gommers L; van Leeuwen LPM; Boerma A; Nijhof SH; van Dort KA; Koopmans MPG; Dalm VASH; Lafeber M; Kootstra NA; Huckriede ALW; van Baarle D; Zaeck LM; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    Lancet Infect Dis; 2023 Aug; 23(8):901-913. PubMed ID: 37088096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.